Actividad Investigadora
Blood test for early diagnosis of escleroderma
Datos básicos
- Código del Financiador:
- NVAL18/11
- Año Inicial:
- 2018
- Año final:
- 2021
Objetivos del proyecto
Systemic sclerosis (SSc) is a very heterogeneous systemic connective tissue disease of unknown etiology with a wide spectrum of manifestations including exacerbated diffuse fibrosis. Currently, the classification used is not sufficient to determine the therapeutic strategy that should be used in a specific patient, at a particular moment of its evolution; therefore, the state of the art is the absence of an effective early diagnosis or treatment along with the difficulties to classify effectively SSc patients. This project faces this urgent need of a biochemical early diagnostic test very well adapted to SSc patients. The SSc-blood test will be applied to plasma samples of the patients to measure Hsp90a, Hsp90ß and TGFß, all of them proteins involved in the fibrotic process developed by these SSc patients. Hence, these proteins could behave as variables in a predictive formula as a diagnostic tool for SSc patients. Secondly, we would apply bootstrapping-validated multiple linear regression and logistic regression analyses of the data acquired from the SSc-blood test to determine the significant positive predictors for SSc progression as an application in a clinical environment in the future. Strategic interest: Our aim is to bring IDIVAL the first known biochemical test applied to the diagnosis of SSc. To be able to achieve this challenge, we aim to demonstrate that Hsp90a, Hsp90ß and TGFß can be used as potential bio-indicators for the early scleroderma diagnoses. This project would be based on a well-established in vitro proof of concept and a multidisciplinary group of recognized experts in molecular biology and SSc. In particular, this project would be founded on a multidisciplinary collaboration between institutions that promote diagnostic innovation with the participation of researchers from IDIVAL, Valdecilla Hospital, University of Cantabria, the Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC) and 12 de Octubre Hospital, in Madrid. Moreover, the project counts with probably the best-characterized cohort of Spanish patients involved in a SSc study.
Documentos
- No hay documentos
Participantes
Unidades de investigación
Financiadores
Resultados del Proyecto
Correlative 3D cryo X-ray imaging reveals intracellular location and effect of designed antifibrotic protein-nanomaterial hybrids
Article. 10.1039/d1sc04183e. 2021
